// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Cost-Effectiveness Analyses of the CONCEPTT Randomized Controlled Trial

HELEN R. MURPHY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Physiologic Pathways in Pregnancy Glycemic Regulation Implicated through Genetic Clustering Analysis

CAMILLE E. POWE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial

HERTZEL GERSTEIN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

N/A

Changes in Dairy Product Consumption and Risk of Type 2 Diabetes among U.S. Men and Women

JEAN-PHILIPPE DROUIN-CHARTIER - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Costarting Sitagliptin with Metformin Is Associated with a Lower Likelihood of Disease Progression in Newly Treated Patients with Type 2 Diabetes

SCOTT A. CAMPBELL - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Sitagliptin

Simplifying Detection of Large Scale Deletions Causing MODY5

AMANDA J. BERBERICH - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Maturity onset diabetes of the young

N/A

Encapsulation of Islets with Tannic Acid Enhances Islet Function

JESSIE BARRA - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Somatostatin

Maladaptive Increases in Skeletal Muscle Ketone Body Oxidation Contribute to Dysglycemia in Mice Subjected to Experimental Obesity

RAMI AL BATRAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Glucoregulatory Effects of Hypothalamic Glucocorticoid Action In Vivo

EMILIE BEAULIEU-BAYNE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hyperglycemia

Glucocorticoid

Role of Delta Cell Gpr120 in the Regulation of Islet Function and Glucose Control

MARINE L. CROZE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Docosahexaenoic acid

Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

JULIO ROSENSTOCK - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Type 2 diabetes mellitus

Linagliptin

SGLT2 Inhibition Suppresses Glucagon Response to Hypoglycemia in Male but Not Female Rats with Streptozotocin-Induced Type 1 Diabetes

CAYLEE A. GREENBERG - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Streptozotocin

A Validation Study of Carbohydrate Intake at Different Glucose Thresholds

NADINE TALEB - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Real-World Evidence that Impaired Awareness of Hypoglycemia Increases Severe Hypoglycemia Rates in T2DM (InHypo-DM Study)

ALEXANDRIA RATZKI-LEEWING - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Risk for Type 2 Diabetes and Cardiovascular Health in Children Treated with Second-Generation Antipsychotics

AMANDA M. HENDERSON - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arterial stiffness

N/A

Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

NIKOLAUS MARX - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Linagliptin

Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes

PAUL WELSH - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Metformin Hydrochloride

Apabetalone (RVX-208) Attenuates an Inflammatory Milieu that Enhances Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Disease Patients

LAURA TSUJIKAWA - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

RVX-208

The Relative Roles of Pro-oxidant Enzymes Nox4 and Nox5 in Diabetic Kidney Disease

JAY C. JHA - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic nephropathy

Alloxan

Renal Hemodynamic and RAAS Profiles in Patients with Type 2 Diabetes (T2D) and Heart Failure (HF)

YULIYA LYTVYN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Angiotensin II

Copyright © 2026. QuantiNova All rights reserved